Hartsell And Associates National Legal Nurse Consulting Services

National Alliance of Certified Legal Nurse Consultants
Nurse Alliance of Tennessee
American Nurses Association

Assisting Attorneys To Victory By Providing Over 33 Years Healthcare Expertise

V.I.P. Member of the Manchester Who's Who Among Executive and Professional Women
V.I.P Member of the Cambridge Who's Who of America

 

Newsletter

November
2007

Volume 1, No 23

 
Asymptomatic Peripheral Artery Disease Prevalence is Rising

News Release 11/04/07

"The prevalence of asymptomatic peripheral artery disease (PAD) is
steadily increasing among American adults, researchers reported at the American Heart Association’s Scientific Sessions 2007.

PAD occurs when fatty deposits accumulate in the inner linings of artery walls, restricting blood flow and needed oxygen to the legs, feet, arms and other areas of the body.   PAD increases the risk of dying from heart disease and stroke.

“We were interested in seeing if the prevalence of peripheral artery disease
in the general U.S. population is increasing, specifically among people who don’t have known coronary artery disease,” said Andrew D. Sumner, M.D., lead author of the study and a cardiologist and medical director of the Heart Station and Cardiac Prevention at Lehigh Valley Hospital in Allentown, Pa.

Researchers hypothesized that the prevalence of asymptomatic PAD is increasing and the escalation is associated with a rise in the prevalence of other common cardiovascular risk factors, including diabetes, smoking, obesity and hypertension.

Sumner and colleagues analyzed data from three successive National Health and Nutrition Examination Surveys (NHANES), conducted in two-year increments between 1999 and 2004.   They identified PAD prevalence by identifying people with an ankle-brachial index of less than 0.9.

“The ankle-brachial index measures the ratio of the blood pressure in the arms and legs, and if it is less than 0.9, people by definition have PAD,” he said.

The researchers then examined the prevalence of associated cardiac risk factors of obesity, diabetes, hypertension and smoking in 5,376 participants, age 40 and older, with no prior history of cardiovascular disease.

They found that PAD prevalence among asymptomatic adults 40 years and older significantly increased from 3.7 percent
in the 1999-2000 survey to 4.2 percent in the 2001-02 survey and 4.6 percent in the 2003-04 survey.

 

 

 

 

 

 

“PAD prevalence was highest among those age 70 and older,” Sumner said.  “But there also was an increase in the prevalence in each adult age group, including 40 to 49, 50 to 69 and greater than 70 years.”

The authors said prevalence of obesity, diabetes, hypertension and smoking also increased over these three surveys.

“PAD is affecting more people in the United States and will continue to do so because the prevalence of this problem increases as we get older, and we have an aging population,” Sumner said.
“And this increase is associated with an increase in common cardiac risk factors.”

Consumers should be aware that while they might not have symptoms, they could have PAD and should discuss risk factors and the possibility of screening with their doctors, Sumner said.

Doctors, on the other hand, should note that PAD prevalence is rising and that many of the accompanying risk factors, such as hypertension, can be treated.

“Doctors need to be looking for PAD in asymptomatic patients,” he said. “And we need to more aggressively address the risk factors associated with this increase in prevalence.” 

The next step, from a public health perspective, is to reassess the protocols and systems that exist for evaluating PAD in asymptomatic people, he said."

Source:  American Heart Association
http://scientificsessions.american
heart.org/portal/scientific
sessions/ss/newsrelease
11.04.07A

Seizure of More Than $300,000 Worth of Products by the FDA

1/01/07

MedWatch - The FDA Safety Information and Adverse Event Reporting Program
 
"FDA notified healthcare professionals of the seizure of more than $300,000 worth of products, including NC Solution, an antifungal product, and other drugs for human or animal use, dietary supplements, and
ingredients to make those products because some lacked FDA approval and all were maintained under grossly unsanitary conditions by General Therapeutics Corp., of St. Louis, Mo. NC Solution is considered a drug because it is intended for use in the diagnosis, cure, or treatment of
disease in people or animals and is not generally recognized as safe and effective for its intended uses. The company does not have FDA approval
for NC Solution.
 
 

Consumers who have any products manufactured by General Therapeutics, including NC Solution, should consult their healthcare provider about discontinuing their use and report if they have experienced any adverse
events that they suspect are related to the use of these products.
 
Read the complete MedWatch 2007 Safety Summary including a link to the FDA Press Release regarding this issue at:"
 
http://www.fda.gov/medwatch/
safety/2007/safety07.htm#NC
 
Source:  Food and Drug
Administration

"Superbug" Bacteria in Schools called MRSA

October 23, 2007

"Reports about a deadly "superbug" bacteria in schools may have you worried. The bacteria, called MRSA, short for Methicillin-resistant Staphylococcus Aureus, is resistant to many medications, making it difficult to treat. Student athletes and young students are among those at risk. You can help protect your children, your other loved ones and yourself by taking a few minutes to learn about MRSA and staph infections and the best ways to prevent their spread."

For the following information:

1.  Introduction
2.  Signs and Symptoms
3.  Causes
4.  Risk Factors
5.  When to seek medical
     advice
6.  Screening and Diagnosis
7.  Treatment
8.  Prevention

http://www.mayoclinic.com
/health/mrsa/DS00735

Source:  The Mayo Clinic

If You Smoke, You Could Have COPD
And Not Know It

Learn about the fourth leading cause of death in the United States:

Click Below to learn more about this Disease:


http://www.nhlbi.nih.gov/health/dci/
Diseases/Copd/Copd_WhatIs.html

Source:  National Heart and Lung Institute of the NIH
 

________________________________

 

If Hartsell and Associates National Legal Consultants Can Assist You,
 Or If You Would Like To See A Particular Subject In The Newsletter, Please Contact Us.  See Below:

         _____________________________________________________________________
 

Telephone:
423-587-2545
 
Electronic Mail:

medlegalanalysis@charter.net   or
hartsell@hartsellmedconsulting.com

Fax:
423-587-2547
 

Back to Newsletter Index Here